课题基金 / 基金详情

T. cruzi-induced Protective and Pathologic CD4 Responses

T. cruzi-induced Protective and Pathologic CD4 Responses
克氏锥虫诱导的保护性和病理性 CD4 反应
批准号:
6511407
负责人:
STUART J KAHN
金额:
$34.2万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-01 至 2005-06-30

项目摘要

项目成果

STUART J KAHN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-term objectives of this research are to understand the mechanisms of chronic inflammatory diseases. Infections initiate or perpetuate many chronic inflammatory diseases. Trypanosoma cruzi infection of mice is an excellent system to investigate infection-induced chronic inflammation. During T. cruzi infection of mammals the CD4 T cell response is critical in controlling the parasite and in generating the chronic inflammation. The T. cruzi antigens of the CD4 response have been unknown limiting further investigations. The T. cruzi trans-sialidase superfamily simultaneously expresses a large number of variant epitopes. The effect of these variant epitopes on the T cell response is unknown. During T. cruzi infection an epitope, epitope 1, of the trans-sialidase superfamily protein SA85-.1, appears to stimulate a large CD4 response. This project investigates this response's contribution in controlling the parasite and causing the ensuing chronic inflammation. Cellular immunology and molecular biology techniques will be used to develop epitope 1- specific T cell clones and TCR transgenic mice. During T. cruzi infection, these T cells will be used to analyze: the size and specificity of the SA85-1.1 protein and epitope 1 responses; the mechanisms used by epitope 1 specific T cell clones to protect, and the clones' ability to cause chronic inflammation; and the naive epitope 1 specific CD4 T cell response and these cells' ability to control T. cruzi and cause chronic inflammation. Completion of these aims will clarify the relationship of T. cruzi-induced protective and inflammatory T cell responses, and will provide insight into infection-induced T cell responses and chronic inflammatory diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
  • 批准号:
    10372803
  • 项目类别:
  • 资助金额:
    $8.02万
  • 财政年份:
    2019
  • 负责人:
    STUART J KAHN
  • 依托单位:
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
  • 批准号:
    10029002
  • 项目类别:
  • 资助金额:
    $120.48万
  • 财政年份:
    2019
  • 负责人:
    STUART J KAHN
  • 依托单位:
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
  • 批准号:
    9789451
  • 项目类别:
  • 资助金额:
    $142.44万
  • 财政年份:
    2018
  • 负责人:
    STUART J KAHN
  • 依托单位:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
  • 批准号:
    10189528
  • 项目类别:
  • 资助金额:
    $65.14万
  • 财政年份:
    2017
  • 负责人:
    STUART J KAHN
  • 依托单位:
海外基金